Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Introduction The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with heterozygous familial hypercholesterolemia or...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Maciej Banach, José Luis López-Sendon, Maurizio Averna, Bertrand Cariou, Megan Loy, Garen Manvelian, Isabela Batsu, Yann Poulouin, Daniel Gaudet
التنسيق: مقال
اللغة:English
منشور في: Termedia Publishing House 2021-10-01
سلاسل:Archives of Medical Science
الموضوعات:
cholesterol
low-density lipoprotein
pcsk9
treatment adherence
الوصول للمادة أونلاين:https://www.archivesofmedicalscience.com/Treatment-adherence-and-effect-of-concurrent-statin-intensity-on-the-efficacy-and,143476,0,2.html

الانترنت

https://www.archivesofmedicalscience.com/Treatment-adherence-and-effect-of-concurrent-statin-intensity-on-the-efficacy-and,143476,0,2.html

مواد مشابهة